Business Context and Reporting Period
Company: Oric Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 13, 2025
Reporting Period: Event date November 13, 2025
Business Context: The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in South San Francisco, CA. Its common stock trades on The Nasdaq Global Select Market under the symbol "ORIC".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of updated corporate presentation materials and does not contain financial statements or quantitative financial data.
Material Changes
The Company announced the inclusion of updated data slides regarding its asset ORIC-944 in its corporate deck for future investor presentations. This update is furnished as Exhibit 99.1.
Guidance, Outlook, and Risks
Management Commentary: The filing serves to disclose the availability of updated ORIC-944 data slides. The Company explicitly states that the information furnished in this Item 7.01 and Item 9.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Risks and Contingencies: No specific risks or contingencies are detailed in the text of this 8-K, other than the standard legal disclaimer regarding the non-filing status of the presentation slides.
Investor Verification Checklist
- Review Exhibit 99.1 (Updated Corporate Presentation Slides) to understand the specific ORIC-944 data updates.
- Verify the legal status of the presentation slides as "furnished" rather than "filed" to understand liability limitations.
- Confirm the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Check subsequent filings for any formal financial updates or clinical trial results referenced in the presentation slides.